|
REV3L expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.75048864292648E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
7.7477024795769E-11 |
| Normal-vs-Stage2 |
5.47299999986706E-07 |
| Normal-vs-Stage3 |
2.70390376755358E-11 |
| Normal-vs-Stage4 |
2.03581596025515E-12 |
| Stage1-vs-Stage2 |
7.383600E-01 |
| Stage1-vs-Stage3 |
6.736300E-02 |
| Stage1-vs-Stage4 |
2.439300E-03 |
| Stage2-vs-Stage3 |
3.705400E-01 |
| Stage2-vs-Stage4 |
3.383900E-02 |
| Stage3-vs-Stage4 |
1.486970E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.19781962126808E-12 |
| Normal-vs-AfricanAmerican |
3.58959999999797E-05 |
| Normal-vs-Asian |
2.36119999996731E-06 |
| Caucasian-vs-AfricanAmerican |
8.400400E-01 |
| Caucasian-vs-Asian |
2.893200E-01 |
| AfricanAmerican-vs-Asian |
5.870600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.7929999707178E-09 |
| Normal-vs-Female |
1.75082170983387E-12 |
| Male-vs-Female |
4.323600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
4.75990025172734E-10 |
| Normal-vs-Age(41-60Yrs) |
3.76659814449454E-11 |
| Normal-vs-Age(61-80Yrs) |
4.91273688396632E-12 |
| Normal-vs-Age(81-100Yrs) |
3.79240000000225E-05 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.326600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
6.177900E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.649700E-02 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.357800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
1.598570E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
3.095200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
4.343800E-02 |
| Classical-VS-Follicular |
5.334800E-01 |
| Classical-VS-Other |
4.570400E-01 |
| Classical-VS-Normal |
2.16080486836745E-11 |
| Tall-VS-Follicular |
2.582800E-01 |
| Tall-VS-Other |
6.566400E-02 |
| Tall-VS-Normal |
1.01050001699576E-09 |
| Follicular-VS-Other |
4.123600E-01 |
| Follicular-VS-Normal |
5.1863000005703E-08 |
| Other-VS-Normal |
6.628100E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
7.24239557214901E-11 |
| Normal-vs-N1 |
1.3767986750679E-11 |
| N0-vs-N1 |
5.172300E-02 |
|
|
